SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

Search

Valneva SE

Open

3.2 -0.62

Overview

Share price change

24h

Current

Min

3.09

Max

3.25

Key metrics

By Trading Economics

Income

-28M

-37M

Sales

7.1M

53M

EPS

-0.25

Profit margin

-69.865

Employees

713

EBITDA

-19M

-26M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+78.13% upside

Dividends

By Dow Jones

Next Earnings

7 maj 2025

Market Stats

By TradingEconomics

Market Cap

-64M

513M

Previous open

3.82

Previous close

3.2

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Valneva SE Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 lis 2024, 10:28 UTC

Major Market Movers

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

3 wrz 2024, 10:28 UTC

Earnings

Pfizer, Valneva Report Positive Lyme Disease Vaccine Candidate Data

15 lis 2024, 10:34 UTC

Market Talk

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

3 wrz 2024, 10:31 UTC

Market Talk

Valneva Shares Gain on Positive Vaccine News -- Market Talk

Peer Comparison

Price change

Valneva SE Forecast

Price Target

By TipRanks

78.13% upside

12 Months Forecast

Average 5.7 EUR  78.13%

High 8.1 EUR

Low 3.3 EUR

Based on 2 Wall Street analysts offering 12 month price targets forValneva SE - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

3.2 / 3.32Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Strong Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.